FIELD OF THE INVENTION
[0001] The present disclosure generally relates to the field of skin care compositions, and in
particular to a composition comprising phytochemicals, addressing the necessity of non-toxic,
economical and effective antibacterial formulation in the field of cosmetic and personal care
products.
BACKGROUND OF THE INVENTION
[0002] Miliaria or prickly heat or heat rash is a characteristic skin ailment of eccrine sweat
gland, which is highly predominant in hot and humid climatic conditions. It has great affinity
towards neonates, as they have immature sweat glands (Bukhari et al., 2016, Our Dermatol
Online, DOI: 0.7241/ourd.20164.123). However, it generally affects people of all ages. It is
characterized by excessive sweating with itchiness and discomfort. It is reported to be the result
of sweat retention, which ultimately leads to the vesicular outbreak followed by maceration
and obstruction of sweat ducts (Anand and Dhyani; 2016; International Journal of Medical
Paediatrics and Oncology, 2, 20-24).
[0003] Depending on the severity of obstruction of sweat ducts, it is divided into three types
namely (i) Miliaria crystalliana - superficial obstruction in stratum corneum; (ii) Miliaria rubra
- obstruction in stratum malpighii with the development of primary lesions; Miliaria pustulosa
- extension of primary lesions with characteristic formation of pustules; (iii) Miliaria profunda – obstruction at or within dermoepidermal junction (Wenzel and Horn 1998; Journal of the American Academy of Dermatology, 38, 1-20). An exemplar study of neonatal cutaneous lesions (conducted at Mahatma Gandhi Medical College and Research Institute Hospital, Pondicherry) revealed the percentage distribution of different types of miliaria in neonates as miliaria rubra (7.0%), miliaria crystallina (4.7%) and miliaria pustulosa (1.0%) (Varghese et al., 2016; International Journal of Health Sciences and Research, 6, 80-92).
[0004] The mismanagement of miliaria may sometimes culminate in serious implications such as anhidrosis wherein, the body fails to perspire, eventually leading to overheating of body and heat stroke (Bukhari et al., 2016). Thus, proper diagnosis and appropriate treatment of miliaria is an indispensable need. Moreover, the pathogenicity of miliaria is manifested primarily to be the result of plugging of sweat duct by periodic acid schiff’s (PAS) positive - extracellular polysaccharide substance (EPS) produced by S. epidermidis (Mowad et al., 1995; Journal of the American Academy of Dermatology, 33, 729-733). S. epidermidis is a Gram positive and commensal microorganism, which turns out to be an opportunistic pathogen on favoring conditions.

[0005] Formerly, the management of miliaria was accomplished using antibiotics such as kanamycin and neomycin. Additionally, chemicals such as salicylic acid, boric acid and chlorphenesin are used in the treatment of miliaria. But these chemicals are reported to possess certain degree of toxic effects on skin and are also reported to be ineffectual at their effective concentration owing to the development of drug resistance (Nitikhunkaesem et al., Powder compositions. U.S. Patent 6,048,549, issued April 11, 2000).
[0006] In view of the above, there is a dire need for antibacterial composition that are non-toxic. Since, natural products are used for centuries as a remedy for curing several human sicknesses, therefore a shift towards the natural product formulation with desired properties would be wise choice. SUMMARY OF THE INVENTION
[0007] In an aspect of the present invention, there is provided an antibacterial composition comprising: a) carvacrol; and b) undecanoic acid, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0008] In an aspect of the present invention, there is provided an antibacterial formulation comprising: i) an antibacterial composition comprising: a) carvacrol; and b) undecanoic acid, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2; and ii) at least one additive.
[0009] In another aspect of the present invention, there is provided a process for preparing the antibacterial composition comprising: a) carvacrol; and b) undecanoic acid, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2, said process comprising steps of: a) obtaining carvacrol; b) obtaining undecanoic acid; and c) contacting carvacrol with undecanoic acid to obtain the composition.
[0010] These and other features, aspects, and advantages of the present subject matter will be better understood with reference to the following description and appended claims. This summary is provided to introduce a selection of concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] The detailed description is described with reference to the accompanying figures. In the figures, the left-most digit(s) of a reference number identifies the figure in which the reference number first appears. The same numbers are used throughout the drawings to reference like features and components.

[0012] Figure 1 illustrates the determination of minimum inhibitory concentration (MIC) of carvacrol and undecanoic acid against S. epidermidis, in accordance with an implementation of the present subject matter.
[0013] Figure 2 illustrates the determination of MIC of zinc oxide and salicylic acid against S. epidermidis, in accordance with an implementation of the present subject matter. [0014] Figure 3 illustrates the determination of degree of synergism between zinc oxide and salicylic acid using checkerboard agar dilution assay, in accordance with an implementation of the present subject matter.
[0015] Figure 4 illustrates images of petri-plates of CFU assay for the assessment of anti¬bacterial activity of carvacrol (C); undecanoic acid (UA) and their synergistic combinations against S. epidermidis, in accordance with an implementation of the present subject matter. [0016] Figure 5 illustrates log reduction of S. epidermidis growth upon treatment with C and UA and their combinations, in accordance with an implementation of the present subject matter.
DETAILED DESCRIPTION OF THE INVENTION
[0017] Those skilled in the art will be aware that the present disclosure is subject to variations and modifications other than those specifically described. It is to be understood that the present disclosure includes all such variations and modifications. The disclosure also includes all such steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any or more of such steps or features. Definitions:
[0018] For convenience, before further description of the present disclosure, certain terms employed in the specification, and examples are collected here. These definitions should be read in the light of the remainder of the disclosure and understood as by a person of skill in the art. The terms used herein have the meanings recognized and known to those of skill in the art, however, for convenience and completeness, particular terms and their meanings are set forth below.
[0019] The articles “a”, “an” and “the” are used to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
[0020] The terms “comprise” and “comprising” are used in the inclusive, open sense, meaning that additional elements may be included. It is not intended to be construed as “consists of only”.

[0021] Throughout this specification, unless the context requires otherwise the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated element or step or group of element or steps but not the exclusion of any other element or steps.
[0022] The term “including” is used to mean “including but not limited to”, “including” and “including but not limited to” are used interchangeably.
[0023] The term ‘MIC’ refers to minimum inhibitory concentration. MIC is the lowest concentration of an antimicrobial (like an antifungal, antibiotic or bacteriostatic) drug that will inhibit the visible growth of a microorganism after overnight incubation. [0024] The term ‘CFU’ refers to colony forming unit. CFU is a unit used to estimate the number of viable bacteria or fungal cells in a sample.
[0025] The term “liquid cleansing product” include shower gel, face wash, body wash, hand wash, and paste. It is apparent that numerous other forms and modifications of the liquid cleansing product will be obvious to those skilled in the art and generally should be construed to cover all such obvious forms and modifications which are within the true spirit and scope of the present disclosure.
[0026] The term “solid cleansing products” include cleansing bars, and films. It is apparent that numerous other forms and modifications of the solid cleansing product will be obvious to those skilled in the art and generally should be construed to cover all such obvious forms and modifications which are within the true spirit and scope of the present disclosure. [0027] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the disclosure, the preferred methods, and materials are now described. All publications mentioned herein are incorporated herein by reference. [0028] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purposes of exemplification only. Functionally-equivalent products, compositions, and methods are clearly within the scope of the disclosure, as described herein.
[0029] As discussed above, previously existing miliaria treatments with antibiotics are reported to be ineffectual at their effective concentration owing to the development of drug resistance. Thus, the present disclosure is aimed to substitute the prevalently used chemical antibacterial agents in anti-miliaria products with plant derived actives and/or reducing the toxic effects and enhancing the antibacterial activity of chemical antibacterial agents by

phytochemicals through combinatorial approach. Accordingly, the composition/formulation of the instant disclosure comprising phytochemicals possesses excellent antibacterial potential. [0030] In an embodiment of the present disclosure, there is provided an antibacterial composition comprising: (a) carvacrol; and (b) undecanoic acid, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0031] In an embodiment of the present disclosure, there is provided an antibacterial composition as described herein, wherein carvacrol to undecanoic acid weight ratio is 1:0.25. [0032] In an embodiment of the present disclosure, there is provided an antibacterial composition as described herein, wherein carvacrol to undecanoic acid weight ratio is 1:0.5. [0033] In an embodiment of the present disclosure, there is provided an antibacterial composition as described herein, wherein carvacrol to undecanoic acid weight ratio is 1:1. [0034] In an embodiment of the present disclosure, there is provided an antibacterial formulation comprising: (i) an antibacterial composition comprising (a) carvacrol; and (b) undecanoic acid, and (ii) at least one cosmetically suitable carrier, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0035] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the at least one cosmetically suitable carrier comprises at least one additive selected from the group consisting of anti-caking agent, absorbent, skin protectant, viscosity modifier, opacifying agent, preservative, skin conditioning agent, cooling agent, odour enhancer, hydrophilic polymer, UV stabilizer, pH adjusting agent, chelating agent, deodorant, perfumes, antimicrobial, antioxidant, humectant, conditioning ingredients, propellants, salts, colorants, dyes, and combinations thereof. [0036] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; and (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0037] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.005 – 0.02% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.003 – 0.0128% with respect to the formulation; and (c) the anti-caking agent having a weight percentage in the range of 62 – 68%

with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0038] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; and (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is 1:0.25.
[0039] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; and (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is 1:0.5. [0040] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; and (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is 1:1. [0041] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; and (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0042] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70%

with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; and (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0043] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; and (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0044] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; and (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2. [0045] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent

having a weight percentage in the range of 0 – 10% with respect to the formulation; and (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2. [0046] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; and (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0047] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation; and (j) the cooling agent having a weight percentage in the range of 0 – 2% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0048] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a

weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation; (j) the cooling agent having a weight percentage in the range of 0 – 2% with respect to the formulation; and (k) the odour enhancer having a weight percentage in the range of 0.5 – 3% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0049] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation; (j) the cooling agent having a weight percentage in the range of 0 – 2% with respect to the formulation; (k) the odour enhancer having a weight percentage in the range of 0.5 – 3% with respect to the formulation; and l) perfume having a weight percentage in the range of 0.5 – 30% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0050] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b)

undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation; (j) the cooling agent having a weight percentage in the range of 0 – 2% with respect to the formulation; (k) the odour enhancer having a weight percentage in the range of 0.5 – 3% with respect to the formulation; l) perfume having a weight percentage in the range of 0.5 – 30% with respect to the formulation; and m) antioxidant having a weight percentage in the range of 0.001 – 5% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
[0051] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein the formulation comprises: (a) carvacrol having a weight percentage in the range of 0.00256 – 0.0256% with respect to the formulation; (b) undecanoic acid having a weight percentage in the range of 0.00128 – 0.0128% with respect to the formulation; (c) the anti-caking agent having a weight percentage in the range of 60 – 70% with respect to the formulation; (d) the absorbent having a weight percentage in the range of 10 – 15% with respect to the formulation; (e) the skin protectant having a weight percentage in the range of 10 – 15% with respect to the formulation; (f) the viscosity modifier having a weight percentage in the range of 0 – 20% with respect to the formulation; (g) the opacifying agent having a weight percentage in the range of 0 – 10% with respect to the formulation; (h) the preservative having a weight percentage in the range of 0 – 5% with respect to the formulation; (i) the skin conditioning agent having a weight percentage in the range of 0 – 1.5% with respect to the formulation; (j) the cooling agent having a weight percentage in the range of 0 – 2% with respect to the formulation; (k) the odour enhancer having a weight percentage in the range of 0.5 – 3% with respect to the formulation; l) perfume having a weight percentage in the range of 0.5 – 30% with respect to the formulation; m) antioxidant having a weight percentage in the range of 0.001 – 5% with respect to the formulation; and n) chelating agent having a weight percentage in the range of 0.001 – 0.2% with respect to the formulation, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.

[0052] In an embodiment of the present disclosure, there is provided an antibacterial formulation as described herein, wherein a) anti-caking agent is talc; b) absorbent is starch; c) skin protectant is selected without limitation from the group consisting of zinc oxide, zinc carbonate, and combinations thereof; d) viscosity modifier is selected without limitation from the group consisting of aluminium starch octenylsuccinate, crosslinked polyacrylate polymers, carboxylic acid polymers, polyacrylamide polymers, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked, and mixtures thereof; e) opacifying agent is selected without limitation from the group consisting of titanium dioxide, diatomaceous earth, calcium carbonate, magnesium carbonate, and combinations thereof; f) preservative is selected without limitation from the group consisting of boric acid, capryloyl salicylic acid, and combinations thereof; g) skin conditioning agent is selected without limitation from the group consisting of salicylic acid, allantoin, calcium salicylate, magnesium salicylate, potassium salicylate, sodium salicylate, panthenol, panthetine, pantotheine, panthenyl ethyl ether, and combinations thereof; h) cooling agent is selected without limitation from the group consisting of menthol, trimethyl isopropyl butanamide, peppermint oil, and combinations thereof; i) odour enhancer is selected from known fragrances; j) perfume is selected without limitation from known fragrances; k) hydrophilic polymer is selected from group consisting of polyethylene glycols (PEGs), polyvinylpyrrolidones (PVP), hydroxypropyl methylcellulose (HPMC), poloxamers, and combinations thereof; l) UV stabilizer is selected without limitation from group consisting of benzophenone-3 and other known UV stabilizers in the art; m) antioxidants is selected without limitation from group consisting of tocopheryl acetate, propyl, octyl and dodecyl esters of gallic acid, butylated hydroxyanisole (BHA, usually purchased as a mixture of ortho and meta isomers), butylated hydroxytoluene (BHT), nordihydroguaiaretic acid, Oxynex (Oxynex ST liquid is a mixture of diethylhexyl syringyliden-emalonate and caprylic/capric triglyceride), vitamin A, vitamin E, vitamin C, and other known antioxidants in the art; n) preservative is selected without limitation from group consisting of phenoxyethanol, benzyl alcohol, methyl paraben, propyl paraben, and combinations thereof; o) pH adjusting agent is selected without limitation from group consisting of lactic acid, citric acid, sodium citrate, succinic acid, phosphoric acid, sodium hydroxide, sodium carbonate, and combinations thereof; q) antimicrobial is selected without limitation from group consisting of farnesol, zinc phenolsulphonate, ethylhexylglycerin, and combinations thereof; r) humectant is selected without limitation from group consisting of tribehenin, glycerine, and combinations thereof; s) propellant is selected without limitation from group consisting of propane, isopropane, butane,

isobutene, and combinations thereof; t) salt is selected without limitation from group consisting of potassium acetate, sodium chloride, and mixtures thereof; u) colorant and dye are selected from group consisting of known colorants in the art; v) chelating agent is selected without limitation from group consisting of ethylene diaminetetraacetic acid (EDTA) , EDTA disodium, calcium disodium edetate, EDTA trisodium, citric acid, EDTA tetrasodium, EDTA dipotassium, and combinations thereof. In another embodiment of the present disclosure, the absorbent is a starch selected from corn starch, maize starch, and other known starches. In yet another embodiment of the present disclosure, the viscosity modifier is selected from well-known compounds as mentioned in Amjad et al., Carbomer Resins: Past, Present and Future Cosmetics & Toiletries 107 (1992), pp 81-85. In an alternate embodiment of the present disclosure, the viscosity modifier is selected from resins consisting of a colloidally water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2.00% of a crosslinking agent such as for example polyallyl sucrose or polyallyl pentaerythritol.
[0053] In an embodiment of the present disclosure, there is provided a process of preparation of an antibacterial composition, wherein the process comprises the steps of a) obtaining carvacrol; b) obtaining undecanoic acid; and c) contacting carvacrol with undecanoic acid to obtain the composition.
[0054] In an embodiment of the present disclosure, there is provided a process for preparation of the antibacterial formulation comprising (i) (a) carvacrol; and (b) undecanoic acid, and (ii) at least one additive, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2, the process comprising the steps of: a) contacting the anti-caking agent, absorbent, and the skin protectant to obtain a first mixture; b) contacting carvacrol, undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent and the first mixture to obtain a second mixture; and c) processing the second mixture to obtain the antibacterial formulation.
[0055] In an embodiment of the present disclosure, there is provided a process for preparation of the antibacterial formulation comprising (i) (a) carvacrol; and (b) undecanoic acid, and (ii) at least one additive, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2, the process comprising the steps of: a) contacting the anti-caking agent, absorbent, and the skin protectant at a temperature in the range of 22 – 28 ℃ at a stirring speed in the range of 20 - 40 rpm for a period in the range of 10 - 120 minutes to obtain a first mixture; b) contacting carvacrol, undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent and the first

mixture at a temperature in the range of 22 – 28 ℃ at a stirring speed in the range of 20 - 40 rpm for a period in the range of 10 – 120 minutes to obtain a second mixture; and c) processing the second mixture to obtain the antibacterial formulation.
[0056] In an embodiment of the present disclosure, there is provided a process for preparation of the antibacterial formulation comprising (i) (a) carvacrol; and (b) undecanoic acid, and (ii) at least one additive, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2, the process comprising the steps of: a) contacting the anti-caking agent, the absorbent and the skin protectant at a temperature in the range of 23 - 27 ℃ at a stirring speed in the range of 25 - 35 rpm for a period in the range of 15 - 115 minutes to obtain a first mixture; b) contacting carvacrol, undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent and the first mixture at a temperature in the range of 23 - 27 ℃ at a stirring speed in the range of 25 - 35 rpm for a period in the range of 15 - 115 minutes to obtain a second mixture; and c) processing the second mixture to obtain the antibacterial formulation.
[0057] In an embodiment of the present disclosure, there is provided a process for preparation of the antibacterial formulation comprising (i) (a) carvacrol; and (b) undecanoic acid, and (ii) at least one additive, wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2, the process comprising the steps of: a) contacting the anti-caking agent, the absorbent and the skin protectant at a temperature in the range of 24- 26 ℃ at a stirring speed in the range of 27 - 32 rpm for a period in the range of 25 - 100 minutes to obtain a first mixture; b) contacting carvacrol, undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent and the first mixture at a temperature in the range of 24 - 26 ℃ at a stirring speed in the range of 27 - 32 rpm for a period in the range of 25 - 100 minutes to obtain a second mixture; and c) processing the second mixture to obtain the antibacterial formulation.
[0058] In an embodiment of the present disclosure, there is provided a process as described herein, wherein the processing the second mixture is carried out by filtration to obtain the antibacterial formulation. Filtration may be carried out using 60 mesh filter. [0059] In an embodiment of the present disclosure, there is provided a formulation as described herein, wherein the formulation is dispensed in a form selected from powders, gels, shower gels, sprays, emulsion, solution, antiseptics, patches, face washes, body washes, hand washes, pastes, solid cleansing products such as cleansing bars and films. In another embodiment of the present disclosure, the formulation is dispensed in the form of powder. EXAMPLES

[0060] The disclosure will now be illustrated with working examples, which is intended to
illustrate the working of disclosure and not intended to take restrictively to imply any
limitations on the scope of the present disclosure. Unless defined otherwise, all technical and
scientific terms used herein have the same meaning as commonly understood to one of ordinary
skill in the art to which this disclosure belongs. Although methods and materials similar or
equivalent to those described herein can be used in the practice of the disclosed methods and
compositions, the exemplary methods, devices and materials are described herein. It is to be
understood that this disclosure is not limited to particular methods, and experimental conditions
described, as such methods and conditions may apply.
[0061] Prickly heat or miliaria is a serious condition that affects the population especially in
hot and humid environment, as prevalent in tropical countries. Though synthetic compositions
are known for treating the condition, herbal formulations provide the possibility of solving the
problem without the adverse side-effects of toxicity and drug-tolerance. The present disclosure
aims to solve said problem by using a synergistic herbal combination of carvacrol and
undecanoic acid.
Ingredients and their sources:
[0062] Carvacrol (C; phytochemical), was procured from Sigma Aldrich, USA.
[0063] Undecanoic acid (UA; phytochemical), was procured from Sigma Aldrich, USA.
Example 1
Determination of minimal inhibitory concentration (MIC) of carvacrol and undecanoic
acid against reference strain S. epidermidis (ATCC 35984):
[0064] Initially, the MIC of carvacrol and undecanoic acid was evaluated using broth micro dilution assay in 96 well microtitre plate. One percent inoculum (v/v) of overnight culture of S. epidermidis was added to 200 μL of tryptic soy broth (TSB) supplemented with cetrimide (positive control) and increasing concentrations (1 μg/mL - 512 μg/mL) of carvacrol and undecanoic acid separately. Wells devoid of treatment and wells containing only TSB was deliberated as control and blank, respectively. The assay was performed in triplicate. The plate was incubated at 37°C for 24 h. Then, the optical density (OD) of the test samples was measured spectrometrically at 600 nm. MIC was determined as minimum concentration at which complete visible growth inhibition is observed. The percentage of growth inhibition was calculated using

[0065] The percentage of growth inhibition by the phytochemicals carvacrol and undecanoic acid are depicted in the Figure 1. Figure 1 clearly shows that carvacrol at 512 μg/mL and undecanoic acid at 256 μg/mL showed significant inhibition of growth (> 95%). Hence, MIC of carvacrol and undecanoic acid was determined as 512 μg/mL and 256 μg/mL, respectively. Example 2
Positive control experiment: Determination of minimal inhibitory concentration (MIC) of zinc oxide and salicylic acid acid against reference strain S. epidermidis (ATCC 35984) [0066] The current line of products for anti-miliaria vastly employ chemicals such as salicylic acid and zinc oxide as antibacterial agents. Thus, zinc oxide and salicylic acid were used as positive controls. Since, the present disclosure is focused to substitute the predominantly used aforementioned antibacterial agents and or enhancing their activity in combination with phytochemicals, determination of MIC of zinc oxide and salicylic acid is mandatory. Owing to the insoluble nature of zinc oxide, MIC of zinc oxide (provided by ITC, LSTC) and salicylic acid (Hi-Media, India) was determined using agar dilution method. Briefly, TSB agar plates supplemented with varying concentrations (1 to 2048 μg/mL) of zinc oxide and salicylic acid separately were prepared. Two micro-liter of overnight culture of S. epidermidis was used to inoculate a spot at center of the agar plates. Plain TSB agar plate and TSB agar plate devoid of treatment was deliberated as blank and control, respectively. Then, the plates were incubated at 37 °C for 24 h. After incubation, the plates were documented using high resolution charge-coupled device (CCD) camera (GelDoc XR+, Bio-Rad).
[0067] As is clear from the Figure 2, zinc oxide and salicylic acid exhibited significant growth inhibition (> 90%) of S. epidermidis at the concentration of 2048 μg/mL. Hence, MIC of zinc oxide and salicylic acid was determined as 2048 μg/mL. Example 3
Checker board assay to determine the synergism between carvacrol and undecanoic acid [0068] To determine the synergism of the combination of phytochemical used (carvacrol + undecanoic acid) two-dimensional checkerboard assay was employed. With the checker board assay the in vitro interactions between carvacrol + undecanoic acid was determined and the results are depicted in Table 1 below.
[0069] Initially, the interactions between carvacrol and undecanoic acid were evaluated using 96 well microtitre plate. Six different concentrations of each drug candidate were tested. carvacrol at MIC (512 μg/mL) was added to the first column of 96 well microtitre plate, which was followed by the addition of two-fold lesser concentration of carvacrol for every consecutive column. Thus, the test concentrations of carvacrol were added in the range of 512 μg/mL to 0

μg/mL. Similarly, undecanoic acid at MIC (256 μg/mL) was added to the first row, which was diluted two-fold lesser concentration for every successive row. The last test concentration of each drug candidate was set at 0 μg/mL, so as to examine the activity of individual drug candidate at various test concentrations in combination. Thus, the combination of two phytochemicals was accomplished in checkerboard broth micro dilution assay. Appropriate control, negative control and blank were considered. Each combination and independent dilutions were made in triplicate in 96 well microtitre plate as two separate experiments. [0070] Table 1

*IC - Inoculum control; Values indicate the FIC index; (+), and (-) indicate the presence and absence of antibacterial activity, respectively.

[0071] Synergistic activity of carvacrol and undecanoic acid analysed through checker board assay is clear from Table 1. The synergism between carvacrol and undecanoic acid was evaluated using the following formula: (Meletiadis et al., Antimicrobial Agents and Chemotherapy, 54, 602-609.2010)
FIC index = FICA + FICB
FICA =MIC of A in combination with B / MIC of A alone
FICB=MIC of B in combination with A / MIC of B alone
FIC index ≤ 0.5 ==synergistic
0.5 > FIC index < 2 == indifferent
FIC index > 2 == Antagonistic
FIC Carvacrol =0.25
FIC Undecanoic acid = 0.25
FICindex = FIC Carvacrol +FIC Undecanoic acid (0.25 + 0.25) [0072] The synergistic antibacterial activity with more than 90% growth inhibition was found in 128 μg/mL+64 μg/mL; 128 μg/mL+32 μg/mL; 64 μg/mL+64 μg/mL combinations of carvacrol and undecanoic acid, respectively and the corresponding FIC indices of aforesaid active combinations are 0.5, 0.375 and 0.375. Example 4
Checker board assay to determine the synergism between zinc oxide and salicylic acid [0073] The in vitro interactions between positive controls zinc oxide and salicylic acid were also tested using agar dilution method. Totally six different concentrations were considered for each drug candidate. Initially, 36 petriplates were aligned in 6 X 6 arrays (i.e. 6 rows & 6 columns). Similar to broth dilution assay, TSB agar supplemented with zinc oxide at MIC (2048 μg/mL) was added to the first column, which was followed by addition of two-fold lesser concentration of zinc oxide to every consecutive column. Thus, the test concentrations of zinc oxide were added in the range of 2048 μg/mL to 0 μg/mL. In a similar way, salicylic acid at MIC (2048 μg/mL) was added to the first row, which was followed by the addition of two-fold lesser concentrations to every consecutive row. The last concentration in agar dilution method was also set at 0 μg/mL, so as to examine the activity of individual drug candidate at various test concentrations in combination. Thus, the combination of zinc oxide and salicylic acid was made using agar dilution method. Two microliter of overnight culture was used to inoculate a spot at the center of the agar plates and incubated at 37 °C for 24 h. After incubation, the plates

were documented using high resolution CCD camera (GelDoc XR+, Bio-Rad). The results are
presented in Figure 3.
[0074] The synergistic antibacterial activity with more than 85% of growth inhibition of S.
epidermidis was observed in 512 μg/mL + 512 μg/mL of zinc oxide and salicylic acid
combination. The corresponding FIC index is 0.5. Moreover, the synergistic concentration of
zinc oxide and salicylic acid combination was found to be approximately four times more than
that of working synergistic concentrations of carvacrol and undecanoic acid. Thus, the
proficient synergistic antibacterial activity of phytochemical combination than chemical based
antibacterial agents is verified. Henceforth, the synergistic phytochemical combination of
carvacrol and undecanoic acid could be used as an effective substitute for prevalently used
antibacterial agents, which are reported to pose certain toxic effects at their effectual
concentration.
Example 5:
Negative example: Checker board assay to determine the in vitro interactions between
phytochemicals
[0075] In order to establish whether the other phytochemical combinations are able to inhibit
S. epidermis with similar intensity and in similar concentrations or not, similar checker board
assays were performed in a manner as described in Example 3. Alternate phytochemicals used
for this experiment were combination of eugenol + undecanoic acid and berberine + undecanoic
acid.
[0076] Initially, the minimum inhibitory concentration (MIC) of phytochemicals namely
eugenol, berberine and undecanoic acid was determined at increasing concentrations (1 to 1024
μg/mL) against Staphylococcus epidermidis (ATCC 35984) using microbroth dilution method
as described earlier in Example 2. Eugenol at 1024 μg/mL, berberine at 256 μg/mL and
undecanoic acid at 256 μg/mL showed significant inhibition of growth (> 95%). Hence, MIC
of eugenol, berberine and undecanoic acid was determined as 1024 μg/mL, 256 μg/mL and
256 μg/mL, respectively.
[0077] Further, two-dimensional checkerboard assay was employed to assess the in vitro
interactions between eugenol + undecanoic acid, and berberine + undecanoic acid. Initially, the
interactions between eugenol and undecanoic acid were evaluated using 96 well microtitre
plate. Six different concentrations of each drug candidate were tested. Eugenol at MIC (1024
μg/mL) was added to the first column of 96 well microtitre plate, which was followed by the
addition of two-fold lesser concentration of eugenol for every consecutive column. Thus, the
test concentrations of eugenol were added in the range of 1024 μg/mL to 0 μg/mL. Similarly,

undecanoic acid at MIC (256 μg/mL) was added to the first row, which was diluted two-fold lesser concentration for every successive row. The combination of two phytochemicals was accomplished in checkerboard broth micro dilution assay as presented in Table 2 below. Appropriate control, negative control and blank were considered. Each combination and independent dilutions were made in triplicate in 96 well microtitre plate as two separate experiments. The other combinations pertaining to berberine + undecanoic acid (see Table 3) were tested in the similar manner. [0078] Table 2: Synergistic activity of eugenol and undecanoic acid.

Concentration of eugenol
1024 μg/mL 512 μg/mL 256 μg/mL 128 μg/mL 64 μg/mL 0 μg/mL

256 μg/mL + / + / + / + / + / + /
ndecanoic acid / 2 .0 / 15 / 1.25 / 1.125 /1.0625 /

128 μg/mL + / + / + / + / - / -

/ 15 / 1.0 / 0.75 / 0.625 /0.5625

64 μg/mL + / + / - / - / - -
/ 1.25 / 0.75 / 0.5 /0375

32 μg/mL + / + / - / - - -
/ 1.125 y0.625 y/0.375

16 μg/mL + / + / - - - -
1. 0625 /0.5625

0 μg/mL + - - - - -
(+), (-) i ndicate the pr esence and ab sence of an tibacterial ac tivity, respec tively. Inocu lum
control was found to be negative for all combinations. Values indicate the fractional inhibitory concentration (FIC) index.

[0079] Table 3: Synergistic activity of berberine and undecanoic acid.

(+), (-) indicate the presence and absence of antibacterial activity, respectively. Inoculum control was found to be negative for all combinations. Values indicate the FIC index. [0080] Eugenol + undecanoic acid, and berberine + undecanoic acid combinations did not reveal inhibition at any concentration (Tables 2, and 3), which clearly shows that not all antibacterial (phytochemicals) combinations are active against S. epidermis. In contrast, Table 1 clearly reveals synergistic combinations, thus highlighting the experimental effort involved in identifying a suitable combination. Example 6
Determination of synergistic inhibition effect of a combination of carvacrol and undecanoic acid by studying colony forming units (CFU) of S. epidermidis

[0081] The antibacterial activity of synergistic combinations of carvacrol and undecanoic acid was further confirmed using colony forming unit (CFU) assay.
[0082] Working synergistic combinations of carvacrol and undecanoic acid (128 μg/mL+64 μg/mL; 128 μg/mL+32 μg/mL; 64 μg/mL+64 μg/mL) and individual drug candidates at synergistic combinations (128 μg/mL, 64 μg/mL, 32 μg/mL) were added separately to the tubes containing 1 mL of TSB. Tubes without any treatment and tubes containing TSB alone were deliberated as control and blank, respectively. All tubes were inoculated with 1% v/v of overnight culture of S. epidermidis and incubated at 37°C for 24 h in shaker incubator (160 rpm). After incubation, the cells were harvested by centrifugation (8000 rpm for 10 min) and subsequently suspended in 1 mL of phosphate buffered saline (PBS). The cell suspensions were serially diluted and 100 μL of 10-6 dilution of each sample was spread over the TSB agar plates. TSB agar plate spread with 100 μL of PBS was considered as blank. The plates were incubated overnight at 37°C for 24 h. Then, the number of colonies in each plate was counted manually and CFU/mL was calculated. The log reduction was calculated using the following formula:
Log reduction = Log (CFU/mLControl) – Log (CFU/mLTreated) [0083] The CFU assay further affirmed that the synergistic combinations of carvacrol + undecanoic acid potentially inhibited the growth of S. epidermidis cells than that of the individual carvacrol and undecanoic acid (Figure 1 & 4). In addition, the log reduction of S. epidermidis growth upon treatment with individual carvacrol and undecanoic acid and their combinations was calculated and depicted as a bar chart (Figure 5). The result reveals that the synergistic combinations of carvacrol + undecanoic acid exhibited more than one log reduction of S. epidermidis growth (~ 99 % of growth inhibition) when compared to that of individual carvacrol and undecanoic acid, which showed less than one log reduction. Altogether, the obtained results verified the anti-miliaria potential of synergistic carvacrol + undecanoic acid combinations than that of their individual effect. Example 6
Formulation comprising carvacrol and undecanoic acid
[0084] The present example depicts the formulation comprising carvacrol and undecanoic acid, wherein the formulation would comprise additives as disclosed previously in the present disclosure. This example, is intended to explain the working template for the commercial application of synergistic combination of carvacrol and undecanoic acid used in the present disclosure. However, this working example does not imply any limitations on the scope of the present disclosure. The ingredients of anti-miliaria or prickly heat powder comprising

synergistic combination of carvacrol + undecanoic acid is mentioned in Table 4 along with the weight percentages.
[0085] Table 4: Ingredients used in the anti-miliaria or prickly heat powder preparation and their respective function(s).

S.No. Name of ingredient % weight Functionality
1. Talc 60 - 70 or Q.S. to 100 Anti-caking agent or feel enhancer
2. Maize starch or corn starch 10 - 15 Absorbent
3. Zinc oxide 10 - 15 Skin protectant
4. Aluminium starch octenylsuccinate 0 - 20 Viscosity increasing agent
5. Titanium dioxide 0 - 10 Opacifying agent
6. Boric acid 0 - 5 Preservative
7. Salicylic acid 0 - 1.5 Preservative or skin conditioning agent
8. Menthol 0 - 2 Cooling agent
9. Carvacrol 0.00256 - 0.0256 Active
10. Undecanoic acid 0.00128 - 0.0128 Active
11. Fragrance 0.5 – 3 Odour enhancer
Example 7
Process of preparation of the formulation
[0086] The formulation as mentioned in Example 6 comprising the two active phytochemicals was prepared as follows: (a) talc, maize or corn starch and zinc oxide were continuously mixed in a blender at a temperature in the range of 22 - 28 ℃ at a stirring speed in the range of 20 -40 rpm for a period in the range of 10 - 120 minutes until a homogenous mixture (first mixture) is obtained; (b) synergistic combination of carvacrol + undecanoic acid, odour enhancer such as fragrances and other optional ingredients such as aluminium starch octenylsuccinate, titanium dioxide, boric acid, salicylic acid and menthol were added to the first mixture at a temperature in the range of 22 - 28 ℃ for a period in the range of 10 - 120 minutes under continuous agitation (20-40 rpm) to obtain a bulk (second mixture); (c) Then, the bulk (second mixture) was processed by passing through a 60 mesh size filter to obtain the formulation.

[0087] Overall, the present disclosure provides a composition/formulation having an antibacterial potential comprising of a combination of carvacrol and undecanoic acid. The efficacy of phytochemical combination was the synergistic effect of the two components, i.e., carvacrol and undecanoic acid. This phytochemical combination can be used as anti-miliaria / antibacterial against prickly heat / heat rash causing bacterial pathogen. [0088] The composition/formulation is effective against S. epidermis which is the primary causal agent in prickly heat rash or miliaria. The composition/formulation comprising carvacrol and undecanoic acid in a ratio range of 1:0.2 – 1:2 was found to synergistically inhibit said bacteria. The combination was found to be more effective than commercial synthetic antibacterial agents such as zinc oxide and salicylic acid. The composition can be easily adapted to obtain useful commercial formulations such as powders gels, sprays, emulsion, solution, antiseptics, gels, patches, face washes, body washes, hand washes, pastes, solid cleansing products such as cleansing bars and films. Thus, the present disclosure is a potent antimicrobial phytochemical composition without the peril of toxicity.
[0089] Although the subject matter has been described in considerable detail with reference to certain examples and implementations thereof, other implementations are possible.

I/We Claim:
1. An antibacterial composition comprising:
a) carvacrol; and
b) undecanoic acid,
wherein carvacrol to undecanoic acid weight ratio is in the range of 1:0.2 – 1:2.
2. The antibacterial composition as claimed in claim 1, wherein carvacrol to undecanoic acid weight ratio is 1:0.25.
3. The antibacterial composition as claimed in claim 1, wherein carvacrol to undecanoic acid weight ratio is 1:0.5.
4. The antibacterial composition as claimed in claim 1, wherein carvacrol to undecanoic acid weight ratio is 1:1.
5. An antibacterial formulation comprising:

a) an antibacterial composition as claimed in any of the claims 1-4; and
b) at least one cosmetically suitable carrier.

6. The antibacterial formulation as claimed in claim 5, wherein the at least one cosmetically suitable carrier comprises at least one additive is selected from the group consisting of anti-caking agent, absorbent, skin protectant, viscosity modifier, opacifying agent, preservative, skin conditioning agent, cooling agent, odour enhancer, hydrophilic polymer, UV stabilizer, pH adjusting agent, chelating agent, deodorant, perfumes, antimicrobial, antioxidant, humectant, conditioning ingredients, propellants, salts, colorants, dyes, and combinations thereof.
7. A process for preparation of the composition as claimed in claim 1, said process comprising the steps of: a) obtaining carvacrol; b) obtaining undecanoic acid; and c) contacting carvacrol with undecanoic acid to obtain the composition.
8. A process for preparation of the antibacterial formulation as claimed in any of the claims 1-6, the process comprising the steps of: a) contacting the anti-caking agent, absorbent, and the skin protectant to obtain a first mixture; b) contacting carvacrol, undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent and the first mixture to obtain a second mixture; and c) processing the second mixture to obtain the antibacterial formulation.
9. The process as claimed in claim 8, wherein contacting the anti-caking agent, the absorbent, and the skin protectant at a temperature in the range of 22 – 28 ℃ at a stirring

speed in the range of 20 - 40 rpm for a period in the range of 10 - 120 minutes to obtain a first mixture.
10. The process as claimed in claim 8, wherein contacting the carvacrol, the undecanoic acid, the odour enhancer, the viscosity modifier, the opacifying agent, the preservative, the skin conditioning agent, the cooling agent, and the first mixture at a temperature in the range of 22 – 28 ℃ at a stirring speed in the range of 20 - 40 rpm for a period in the range of 10 – 120 minutes to obtain a second mixture.
11. The formulation as claimed in any of the claims 5-6, is dispensed in a form selected from powder, gel, spray, emulsion, solution, antiseptics, patches, liquid cleansing product, solid cleansing product. cleansing bars, films.